Chengdu Olymax In-Licenses China Rights to Australian Strep Vaccine Candidate

Chengdu Olymvax Biopharma has in-licensed greater China rights to a novel Group A Streptococcus (GAS) vaccine developed by Australia's Griffith University. Olymvax will manufacture the vaccine for Phase I clinical trials that will be conducted concurrently in China and Australia. The needle-free vaccine is delivered in a single dose through the nose, which facilitates access to lung lining tissue, the location for most strep infections.Olymvax will pay Griffith royalties on sales and also make milestone payments. Specific details of the agreement were not disclosed. More details.... Share this with colleagues: // //  
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.